Antibody-Drug Conjugates for Ovarian Cancer — An Interview with Dr Kathleen N Moore (Companion Faculty Lecture)
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to Cart failed.
Please try again later
Add to Wish List failed.
Please try again later
Remove from wishlist failed.
Please try again later
Adding to library failed
Please try again
Follow podcast failed
Please try again
Unfollow podcast failed
Please try again
Antibody-Drug Conjugates for Ovarian Cancer — An Interview with Dr Kathleen N Moore (Companion Faculty Lecture)
-
Narrated by:
-
By:
Featuring a slide presentation and related discussion from Dr Kathleen N Moore, including the following topics:
- Overview of developments and opportunities with antibody-drug conjugates (ADCs) in ovarian cancer(0:00)
- Targeting folate receptor alpha with mirvetuximab soravtansine (3:59)
- Targeting TROP2 with ADCs (9:12)
- Targeting folate receptor alpha with ADCs (14:17)
- Targeting cadherin-6 with ADCs (17:27)
- Targeting HER2 with ADCs (26:12)
- Potential of ADCs in the treatment of platinum-sensitive ovarian cancer (28:38)
CME information and select publications
No reviews yet